Sarepta Therapeutics (SRPT) Q3 2026 earnings review
Sarepta's older drugs hold steady, but gene therapy sales slip
Sarepta, which sells medicines for the muscle disease Duchenne, held its older drugs steady while its gene therapy slipped again. Product sales fell 13% from a year ago because its gene therapy, ELEVIDYS, sold far less. Chief executive Michael Severino still raised the bottom of the full-year sales range. A one-time $62 million factory charge turned the quarter into an operating loss.
| Product sales | $323.8M −13% from a year ago |
|---|---|
| ELEVIDYS sales | $83.5M −15% from last quarter |
| Operating profit, excluding one-offs | $22.9M −$35.7M a year ago |
| Full-year product sales outlook | Low end raised $50M middle of the range: $1.275B |
⚖️ Verdict: 🟢 Bullish
The story got better, because the older drugs now carry the business and Sarepta raised its sales plan to match. Costs came in lower, so cash grew. The bad news: ELEVIDYS sales have dropped four quarters running, and by our math the plan still leaves fourth-quarter sales below the third.
The question now is whether ELEVIDYS demand has stopped shrinking. Severino sees room for growth from new data and a larger sales team, while flat enrollment forms point to sales staying near today's level. ELEVIDYS sales in the first half of 2027 will tell.
🐂 Bull Case
Sarepta's Older Duchenne Drugs Sold More
Sarepta sells three PMO drugs, older Duchenne medicines that patients take as weekly infusions. Their sales reached $240.3 million, 4.2% above the second quarter. Chief commercial officer Patrick Moss said "New patient enrollments increased" in the period.
- PMO share of product sales: 74%, against 64% a year ago
- PMO sales outside the US: up 22% from a year ago
- PMO sales in the US: down 2.3% from a year ago
This matters because the three drugs now fund most of the business while ELEVIDYS, the gene therapy, shrinks. But the gain came from other countries, so the US base only held steady. That is still useful, because steady patients mean steady cash.
What to watch: PMO sales for the fourth quarter, reported early next year. A figure near $240 million again would show the drugs kept their patients before a rival exon 51 drug arrives.
Lower Costs Let Sarepta Add Cash
In July 2025 Sarepta started a restructuring to cut costs, and it halted most of its gene therapy work. Spending on research and overhead, excluding one-offs, came to $169 million, 40% below a year ago.
Most of that drop reflects a $100 million payment to partner Arrowhead last year. Without it, by our math, the spending still shrank about 8%. Cash and investments reached $998.7 million, up $54 million since June.
Finance chief Ryan Wong said the base business produced "nearly $300 million of cash year-to-date", not counting payments to Arrowhead. That matters because the cash covers the convertible notes due in September 2027 and still funds late-stage trials.
What to watch: fourth-quarter spending, reported early next year. The new plan leaves room for a much larger quarter, so a figure near the third quarter's would show the savings are holding.
Sarepta's Own Sales Plan Looks Cautious
In August, Sarepta set a full-year range for product sales, which covers its PMO drugs and the ELEVIDYS gene therapy. By our math, that range left about $270-320 million a quarter for the second half. Third-quarter sales came in at $323.8 million, just above the top.
The new range runs to $1.3 billion, yet even its top leaves the fourth quarter below the third, by our math. Sarepta expects ELEVIDYS to stay near its third-quarter level, and it "expects the PMO franchise to remain strong". At the middle of the range, the PMO drugs would bring in only about $209 million.
So the plan looks cautious, but that is a fact about the plan, not about demand. ELEVIDYS sales still fell, and the first reading on the new sales push comes in 2027.
What to watch: full-year product sales, due early next year. A total above $1.3 billion would mean the fourth quarter simply repeated the third.
Sarepta Prepares Late-Stage Trials Before Its Data Arrive
Sarepta licensed siRNA drugs from Arrowhead, medicines that silence a faulty gene's message inside muscle cells. The lead two target DM1 and FSHD, inherited muscle-wasting diseases with no approved treatment that alters their course. Data from repeated doses arrive within weeks.
- siRNA research spending: $13.1 million, up 72% from a year ago
- Phase 3 preparation: Sarepta is "beginning manufacturing of clinical supply"
- Lab data: SRP-1003, the DM1 drug, cut the disease-causing RNA inside the cell nucleus
Chief executive Michael Severino set a bar. A Novartis drug corrected faulty splicing, the way cells edit genetic messages, by "perhaps in the 10%-15% range", he said. "We certainly want to be well above that." No human repeated-dose results exist yet, so this quarter cannot test that claim. A weak readout would remove the main reason for the extra spending.
What to watch: the splicing correction figure in the DM1 results, expected within weeks. A result well above the Novartis range would support the move to Phase 3.
🐻 Bear Case
ELEVIDYS Sales Fell Again With No Recovery Date
ELEVIDYS is Sarepta's one-time gene therapy for boys with Duchenne who can still walk. Chief commercial officer Patrick Moss said "we are seeing stabilization in the business", and the company kept its plan for fourth-quarter sales in line with the third.
The numbers do not show stability yet. Sales fell to $83.5 million, 15% below the second quarter. That makes four quarterly declines in a row. Enrollment forms, the paperwork that starts a treatment, came in "in line with Q2", and Sarepta again gave no count.
Chief executive Michael Severino said current infusions come from forms filed before the new sales push and data. He called the quarter "essentially a clean baseline". That is fair, because treatment starts about six months after a form. But flat forms point to flat sales into early 2027.
By our math, full-year ELEVIDYS sales will land near $367 million if the fourth quarter matches the third. Sarepta reconfirmed a $500 million floor in January and did not mention it this quarter.
What to watch: ELEVIDYS sales in the first half of 2027, the first fed by forms filed after the push began. Sales still near $83 million would mean the push has not lifted demand.
A $62 Million Factory Charge Erased Quarterly Profit
Sarepta pays contract manufacturer Catalent for a fixed amount of ELEVIDYS production. In September it "elected not to manufacture certain inventories", so it booked a $62.0 million charge in cost of sales. An October amendment "reduced the Company's committed manufacturing batch quantity".
- Cost of sales: 49.4% of revenue, up 11.7 percentage points from a year ago
- The charge alone: 16.3 percentage points of revenue
- Operating result: a $9.0 million loss, or a $53 million profit without the charge, by our math
- Manufacturing commitments: $354.1 million, down from $428.0 million in June
The charge buys relief from future bills, but $169.0 million of commitments still fall due in the fourth quarter. That equals about half of a quarter's product sales, so the factory bill remains large for a smaller business.
What to watch: cost of sales as a share of revenue next quarter. A return near last year's level would show the charge was a one-time cleanup.
The Older Drugs Face FDA Ruling and Rival
Two of Sarepta's PMO drugs, AMONDYS 45 and VYONDYS 53, sell under accelerated approval. That is a provisional US approval which needs a confirming trial, and that trial, ESSENCE, missed its main goal in 2025. The FDA will rule on full approval by February 28, 2027.
The third drug, EXONDYS 51, faces a rival from Dyne. Chief executive Michael Severino said his "baseline assumption is that Dyne will get their approval in early 2027". He also said "wholesale switching of stable patients is not likely early on", with any effect showing "more towards the back end of 2027".
This matters because Sarepta funds its new drugs from PMO cash. In the second quarter, AMONDYS 45 and VYONDYS 53 made up 48% of PMO sales. Strong current sales show patients staying today, but they cannot show what regulators or a rival will do next year.
What to watch: the FDA decision on AMONDYS 45 and VYONDYS 53, due February 28, 2027. A conversion to full approval would remove the threat to about half of PMO sales.
Risks this quarter didn't answer
Several standing concerns got no reading that settles them this quarter, although court rulings moved two of them partly. Each item below names the event that would decide it.
- Shareholder lawsuits: a court dismissed the securities class action in September, and the plaintiffs appealed in October; the appeal ruling decides it.
- Patent cases: Sarepta paid REGENXBIO $39.0 million to settle, but a Genzyme patent trial over ELEVIDYS is set for June 14, 2027.
- 2027 convertible notes: $158.6 million falls due in September 2027; repayment from cash closes the item.
- New chief executive: Michael Severino joined in July; the DM1 and FSHD data and the Phase 3 decision are his first test.
- Share buybacks: none since early 2025 under the $500 million program; a statement on the program would answer it.
💲 Other KPIs
Inventory fell again, to 2.1% below December and 15.6% below a year ago. Most of it is ELEVIDYS and PMO material still in production. The stock equals about 3.3 quarters of product sales, against 3.4 in June. This year Sarepta wrote off $11.6 million of obsolete ELEVIDYS stock.
Deferred revenue, value Sarepta booked from its Roche deals but has not yet earned, fell to $188.8 million from $220.3 million in June. It stood at $527.3 million in December, before Roche declined an option. Supply sales to Roche now draw it down, and that supply turned a $2.5 million profit after a loss in the second quarter.
Debt held near $857 million; the rise from $829 million in December is non-cash interest, not new borrowing. Of it, $158.0 million is now current, because the 2027 notes mature in September 2027. Interest expense more than doubled from a year ago, because the 2030 notes carry a higher rate.
🔮 Guidance
Raised. The bottom of the full-year sales range rose by $50 million, while the top stayed put. By our math, the middle leaves about $292 million for Q4, 10% below Q3. That would also sit 21% under a year ago. It is the first upward move this year, after a cut in August.
Unchanged. Sarepta still expects the same range from Roche deals, supply sales and royalties. Nine months brought in $530.4 million, so by our math Q4 needs about $45 million at the middle. That compares with $57.6 million in Q3, because the rest of the year consists mainly of supply sales and royalties.
Cut. The top of the range for research and overhead spending, including stock pay and depreciation, dropped by $25 million. Nine months came to $662.9 million, so by our math Q4 would run near $300 million at the middle. That is about 49% above Q3.
Cut. The plan for research and overhead spending, excluding one-offs, now tops out $25 million lower. By our math, that leaves about $255 million for Q4, 51% above Q3. Sarepta did not break down the extra spending, though it has begun making supply for Phase 3 trials.
Unchanged. Sarepta expects fourth-quarter ELEVIDYS sales near the Q3 level, "subject to normal variability associated with one-time gene therapy". By our math, that would be about 24% below a year ago. A heavy flu season had already pushed six infusions out of that quarter.
❓ Key Questions
How many ELEVIDYS enrollment forms did Sarepta receive?
Sarepta has described the forms as improving or steady for four quarters without giving a count. A number per quarter, and the share that led to an infusion, would show whether the new sales push works.
Why does the sales range leave Q4 below Q3?
Sarepta expects steady ELEVIDYS and strong PMO sales, yet by our math even the top of its range implies a weaker fourth quarter. Investors need to know whether that gap is caution or a known effect.
Is the $500 million ELEVIDYS sales floor still in place?
Sarepta reconfirmed the floor for 2026 in January. By our math, the year will end near $367 million, and Sarepta has not said whether it dropped the target.
What would an FDA rejection mean for AMONDYS and VYONDYS?
The two drugs made up about half of PMO sales in the second quarter. Sarepta has not said whether it would keep selling them, change their labels or withdraw them after a negative February decision.
What will the extra fourth-quarter spending pay for?
By our math, the spending plan leaves about $255 million for Q4, half again the third quarter. A split between Phase 3 preparation and other costs would show the running rate for 2027.